Advertisement
Advertisement
PHAR
Pharming Group N.V. ADS, each representing 10 ordinary shares
12.29
USDSponsored
-0.01
-0.08%
Nov 06, 15:49 UTC -5
Closed
After-Market
12.28
-0.01
-0.08%
Pharming Group N.V. ADS, each representing 10 ordinary shares (PHAR) Earnings
PHAR Earnings Reports
Positive Surprise Ratio
PHAR beat 21 of 43 last estimates.
49%
Next Report
Date of Next Report
Mar 10, 2027
Estimate for Q4 26 (Revenue/ EPS)
$116.62M
/$0.02
Implied change from Q3 26 (Revenue/ EPS)
-0.84%
/-93.33%
Implied change from Q4 25 (Revenue/ EPS)
+9.47%
/--
Pharming Group N.V. ADS, each representing 10 ordinary shares earnings per share and revenue
On Oct 27, 2026, PHAR reported earnings of 0.30 USD per share (EPS) for Q3 26, beating the estimate of 0.02 USD, resulting in a 1165.82% surprise. Revenue reached 117.60 million, compared to an expected 111.34 million, with a 5.62% difference. The market reacted with a -0.25% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 0.02 USD, with revenue projected to reach 116.62 million USD, implying an decrease of -93.33% EPS, and decrease of -0.84% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
FAQ
What were Pharming Group N.V. ADS, each representing 10 ordinary shares's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Pharming Group N.V. ADS, each representing 10 ordinary shares reported EPS of $0.30, beating estimates by 1165.82%, and revenue of $117.60M, 5.62% above expectations.
How did the market react to Pharming Group N.V. ADS, each representing 10 ordinary shares's Q3 2026 earnings?
The stock price moved down -0.25%, changed from $11.90 before the earnings release to $11.87 the day after.
When is Pharming Group N.V. ADS, each representing 10 ordinary shares expected to report next?
The next earning report is scheduled for Mar 10, 2027.
What are the forecasts for Pharming Group N.V. ADS, each representing 10 ordinary shares's next earnings report?
Based on --
analysts, Pharming Group N.V. ADS, each representing 10 ordinary shares is expected to report EPS of $0.02 and revenue of $116.62M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.